1. Introduction {#sec1}
===============

There are many supraglottic airway devices (SADs) which are used for the management of a difficult airway and as a conduit for tracheal intubation \[[@B1]\]. The endotracheal intubation assisted by SADs has many advantages including easy insertion, better alignment of the glottis opening, and continuous patient oxygenation and ventilation. Moreover, the haemodynamic stress response to intubation by SAD is less than that of direct laryngoscope \[[@B2]\]. Also, these devices can be a good alternative for patients with previous history of difficult intubation, restricted neck mobility, and stability of cervical spine \[[@B3]\]. Moreover, SAD provides the ability to overcome upper airway obstruction and provision of a hands-free airway with a relatively straightforward path to the larynx \[[@B4]\].

Among these SADs, Air-Q Intubating Laryngeal Airway (air-Q, Mercury Medical, Clearwater, FL, USA) is a SAD intended for allowing for airway maintenance under general anesthesia as well as an aid for tracheal intubation with a cuffed tracheal tube in both adults and pediatric patients. The design of air-Q includes a large airway tube inner diameter (ID), a short airway tube length, and a tethered, removable standard 15 mm circuit adapter \[[@B5]\]. Also, specially designed ridges inside mask cavity provide lateral stability to help prevent tip from bending backward and improve mask seal. These features enable direct insertion of a curved shaft, the lack of a grill in the ventilating orifice, and an easily removable airway adapter \[[@B5]\].

Several studies reported the efficacy of air-Q in pediatric patients comparing other airway devices such as laryngeal mask airway (LMA), i-gel, Aura-I, Cobra Perilaryngeal Airway (CobraPLA), and fiberoptic guided intubation. However, the findings are variable and the reported outcomes from several studies are conflicting. To date, no systematic review nor meta-analysis regarding air-Q has been performed. Therefore, we aimed to evaluate the efficacy of air-Q compared with other airway devices in pediatric patients.

2. Methods {#sec2}
==========

This systematic review was conducted following the guidelines of the PRISMA statement \[[@B6]\].

2.1. Systematic Search {#sec2.1}
----------------------

We conducted a systematic review and meta-analysis for RCTs which compared the air-Q with the other airway device during general anesthesia in pediatric patients. Literature searches were conducted in MEDLINE, EMBASE, Cochrane Library, KoreaMed, KMBASE, and Google Scholar inclusive at June 1, 2014, and updated at September 2015. The search strategy combining free text and related search is attached in the Appendix.

2.2. Selection of Included Studies {#sec2.2}
----------------------------------

The study\'s inclusion and exclusion criteria were determined before systematic search. Two review authors (Eun Jin Ahn and Si Ra Bang) independently scanned the titles and abstracts identified by the variety of search strategies described above. If the report was determined not eligible from the title or abstract, the full paper was retrieved. Potentially relevant studies, chosen by at least 1 author, were retrieved and evaluated in full-text versions. The articles that met the inclusion criteria were assessed separately by 2 authors (Eun Jin Ahn and Si Ra Bang), and any discrepancies were resolved through discussion. If agreement would not be reached the dispute was resolved with the help of third investigator (Hyun Kang).

2.3. Inclusion and Exclusion Criteria {#sec2.3}
-------------------------------------

We included randomized controlled trials which compared the air-Q and the other airway device during general anesthesia in pediatric anesthesia. The group used air-Q as an airway device considered as an experimental group. Otherwise, group used other laryngeal mask airway devices and fiberoptic bronchoscope as an airway device considered as a control group. We excluded data from abstracts, posters, case reports, comments or letters to the editor, reviews, and animal studies. There was no limitation in language to select studies.

2.4. Study Outcomes {#sec2.4}
-------------------

The outcome data were divided into two series as if the air-Q is used as a SAD or used as a conduit of tracheal intubation. In series of air-Q used as SAD, the outcomes included success rate of insertion of airway device, oropharyngeal leakage pressure, insertion time, and ease of insertion airway device. In series of air-Q used as a conduit of intubation, the outcomes included success rate of intubation, the number of attempts, intubation time, and fiberoptic glottis view. Also, complications including desaturation, sore throat, blood staining of device, and laryngospasm were evaluated.

We compared the number of attempts through the rate of successful intubation at first attempt. Ease of insertion of airway device or intubation through airway device was analyzed by comparing the number of easiest level of difficulty. The extracted outcome data of fiberoptic glottis view grade were divided into 4 grades \[[@B9]--[@B10]\] (visible vocal cords/visible vocal cord with posterior epiglottis/visible vocal cord with anterior epiglottis/no visible vocal cord) or 5 grades \[[@B12]--[@B15]\] (visible vocal cords/visible vocal cord with posterior epiglottis/vocal cord anterior visible \<50% obstruction/visible vocal cord with anterior epiglottis, \>50% obstruction/no visible vocal cord). The scenarios were divided into best and worst which include the incidence of fiberoptic glottis view grade with visible vocal cord and no visible vocal cord.

We performed subgroup analyses for comparing groups, SADs, and fiberoptic guided intubation. SADs were also divided into Aura-I, CobraPLA, i-gel, and LMA series which include LMA-Unique and LMA-Flexible. We also performed subgroup analyses based on the generations of SADs. First-generation devices included LMA-Unique, LMA-Flexible, and CobraPLA. The second-generation devices included Aura-I, i-gel, and LMA-Fastrach. The sensitivity analysis was performed to rule out the excessive effect of single study on heterogeneity.

2.5. Validity Scoring {#sec2.5}
---------------------

The quality of eligible studies was assessed independently by two authors (Chong Wha Baek and Yong Hun Jung) of our review group using the tool of "risk of bias" according to Review Manager software (version 5.3, the Cochrane Collaboration, Oxford, UK). The quality was evaluated based on the following seven potential sources of bias: random sequence generation; allocation concealment; blinding of the participants and their parents; blinding of outcome assessment; incomplete outcome data; selective reporting. The methodology of each trial was graded as "high," "low," or "unclear," to reflect a high risk of bias, low risk of bias, and uncertainty of bias, respectively ([Table 3](#tab3){ref-type="table"}).

2.6. Data Extraction {#sec2.6}
--------------------

All interrelated data in each included study were independently extracted onto a spreadsheet by 2 authors (Eun Jin Ahn and Geun Joo Choi) and cross-checked. The spreadsheet included the following indexes: (1) name of first author, (2) year, (3) name of journal, (4) study design, (5) registration of clinical trial, (6) risk of bias, (7) number of patients in study, (8) sex of patients, (9) age, (10) weight, (11) height, (12) ASA physical status, (13) type of surgery, (14) number and experience of device user, (15) number of allowance of insertion trials, (16) device size, (17) induction method, (18) maintenance agent, (19) use of muscle relaxant, and (20) intervention/control. If there were missing data, we made attempts to contact the authors to chase the data of included studies. And if the author could not be contacted, the data were acquired from estimated value in the figure or graph.

2.7. Statistical Analysis {#sec2.7}
-------------------------

We conducted this meta-analysis by Review Manager (version 5.3, the Cochrane Collaboration, Oxford, UK) and Comprehensive Meta-Analysis software (version 2.0, Biostat, Englewood, NJ, USA). Three authors (Eun Jin Ahn, Geun Joo Choi, and Young Cheol Woo) independently input all data to the software. For dichotomous data, we calculated pooled risk ratio (RR), odds ratio (OR), and 95% confidence intervals (CIs). If the 95% CI included a value of 1, we considered the difference not to be statistically significant. We calculated the mean difference for continuous data, also reported with 95% CI. We used the Chi-squared test and the *I*-squared test for heterogeneity. A level of 10% significance (*P* \< 0.1) for the Chi-squared statistic or *I* ^2^ greater than 50% was considered to indicate considerable heterogeneity. The Mantel--Haenszel random-effect model was used for these studies. The Mantel--Haenszel fixed model was used for studies that did not demonstrate significant heterogeneity \[[@B16], [@B17]\]. For data expressed with median and interquartile range, we changed mean and standard deviation via data extraction method from Cochrane handbook for systematic reviews of intervention \[[@B16]\].

We estimated publication bias using Begg\'s funnel plot and Egger\'s linear regression test. If the funnel plot was visually asymmetrical or the *P* value was found to be \<0.1 using Egger\'s linear regression test, the presence of a possible publication bias was identified \[[@B18]\].

3. Result {#sec3}
=========

The search of MEDLINE, EMBASE, Cochrane Library, KoreaMed, KMBASE, and Google Scholar produced 79 studies. After adjusting for duplicates, 49 studies remained. Of these, 34 studies were discharged because it appeared that these studies were out of interest after reviewing the title and abstracts. The full texts of the remaining 15 studies were reviewed in more detail and 10 studies were excluded \[[@B2], [@B5], [@B19]--[@B26]\]. Also, by searching studies which were published after first search date (June 1, 2014), 5 more studies were found \[[@B11], [@B15], [@B8]--[@B10]\]. Thus, 10 studies with a total of 789 patients were included in the final analysis, met the inclusion criteria, and were included in this systematic review and meta-analysis \[[@B27]--[@B10]\] ([Figure 1](#fig1){ref-type="fig"}).

Two of these studies used self-pressurizing air-Q rather than original air-Q which require cuff inflation \[[@B14], [@B15]\]. The air-Q was compared with three types of airway managements: other supraglottic airway devices (SADs) \[[@B27]--[@B10]\] and fiberoptic tracheal intubation \[[@B27]\]. SAD types include LMA-Flexible in one RCT \[[@B8]\]; LMA-Unique in two RCTs \[[@B12], [@B14]\]; Aura-I in three RCTs \[[@B13], [@B7], [@B10]\]; Cobra Perilaryngeal Airway in one RCT \[[@B9]\]; and i-gel in two RCTs \[[@B11], [@B15]\].

Among SADs comparing air-Q, LMA-Flexible, LMA-Unique, and Cobra Perilaryngeal Airway were first-generation SADs \[[@B12], [@B14], [@B9], [@B8]\]. Aura-I and i-gel were second-generation SADs \[[@B13], [@B11], [@B15], [@B7], [@B10]\]. The summary of included studies is described through Tables [1](#tab1){ref-type="table"} [](#tab2){ref-type="table"}--[3](#tab3){ref-type="table"}.

3.1. Risk of Bias {#sec3.1}
-----------------

In all the included studies, the random sequence generation method was performed and seven studies used allocation concealment \[[@B12], [@B14], [@B15]--[@B10]\]. Three RCTs were registered in clinical trial \[[@B12], [@B13], [@B15], [@B10]\] and no incomplete data was reported. All included studies reported no sponsorship. The overall risks of bias are shown in [Table 4](#tab4){ref-type="table"}.

3.2. Air-Q Used as SAD {#sec3.2}
----------------------

### 3.2.1. Oropharyngeal Leakage Pressure {#sec3.2.1}

The oropharyngeal leakage pressure (OLP) was compared to other SADs in nine studies \[[@B12]--[@B10]\]. The combined results showed no evidence for a difference, MD −0.00 (−2.19 to 2.18), *P* \< 0.00001, *I* ^2^ = 91%. Performing subgroup analysis based on the generations of the airway devices, the OLP in air-Q showed no evidence of difference compared to first generations of SADs \[[@B12], [@B14], [@B9], [@B8]\], RR −0.04 (95% CI −3.51 to 3.42), *P* \< 0.00001, *I* ^2^ = 91%. Also, the OLP in air-Q comparing to second generations of SADs showed no evidence of difference \[[@B13], [@B11], [@B15], [@B7], [@B10]\], RR −0.04 (95% CI −3.24 to 3.33), *P* \< 0.00001, *I* ^2^ = 93%. However, by combining three studies \[[@B13], [@B7], [@B10]\] among second generations of SADs which compared OLP of air-Q and Aura-I, the OLP was significantly higher in Air-Q group than Aura-I with substantial heterogeneity, MD 2.09 (0.47 to 3.71), *P* = 0.13, *I* ^2^ = 51%.

### 3.2.2. Success Rate of Device Insertion {#sec3.2.2}

Success rate of device insertion was compared in seven studies \[[@B12]--[@B14], [@B15], [@B8]--[@B10]\]. The combined results showed no evidence for a difference, RR 1.00 (0.98 to 1.03), *P* = 0.90, *I* ^2^ = 0%. In most studies, the success rate of device insertion was 100%. Only in one study \[[@B10]\], the success rate of device insertion of air-Q was 97.5% (39/40).

### 3.2.3. Device Insertion Time {#sec3.2.3}

Device insertion time was compared in eight studies \[[@B12]--[@B11], [@B9]--[@B10]\]. The combined results showed no evidence for a difference, MD 0.69 (−1.00 to 2.38), *P* \< 0.00001, *I* ^2^ = 91%. However, in subgroup analysis by combining three studies \[[@B13], [@B7], [@B10]\] which compared device insertion time of air-Q and Aura-I, the insertion time appeared significantly longer in air-Q group than Aura-I with substantial heterogeneity, MD 3.57 (0.97 to 6.17), *P* = 0.0002, *I* ^2^ = 88%. Throughout sensitivity analysis excluding the study of Kleine-Brueggeney et al. \[[@B10]\], the result became significant without heterogeneity which implies that the insertion time of air-Q was longer than Aura-I, MD 1.90 (1.06 to 2.73), *P* = 0.42, *I* ^2^ = 0%. Insertion time of air-Q was compared to LMA series in three studies \[[@B12], [@B14], [@B8]\]. The combined results showed no evidence for a difference in insertion time of air-Q compared to LMA series, MD −0.48 (95% CI −2.29 to 1.32), *P* = 0.001, *I* ^2^ = 85%. However, in single study \[[@B11]\], insertion time of air-Q compared to i-gel was significantly shorter (16.7 \[4.1\] versus 19.6 \[4.7\]).

### 3.2.4. Ease of Insertion {#sec3.2.4}

Ease of insertion was compared to other SADs in five studies \[[@B12]--[@B14], [@B15], [@B10]\]. The combined results showed the ease of insertion in air-Q was significantly lower than other SADs, RR 0.88 (95% CI 0.81 to 0.95), *P* = 0.40, *I* ^2^ = 0% ([Figure 2](#fig2){ref-type="fig"}).

3.3. Air-Q Used as a Conduit of Intubation {#sec3.3}
------------------------------------------

### 3.3.1. Total Success Rate of Intubation {#sec3.3.1}

The total success rate of intubation was compared to other airway devices in five studies \[[@B27], [@B13], [@B11], [@B9], [@B10]\]. Among these studies, four studies performed the assisted fiberoptic intubation through the airway devices. However, in the single study of Kleine-Brueggeney et al. \[[@B10]\], both groups performed blind intubation through the airway devices rather than assisted fiberoptic intubation. The combined results of five studies could not reveal the significant outcome (RR 0.97, 95% CI 0.85 to 1.11, *P* = 0.09, *I* ^2^ = 51%). Performing sensitivity analysis with removing Kleine-Brueggeney et al.\'s study, the result showed a tendency of the total success rate of air-Q which was lower than other airway devices, RR 0.95 (95% CI 0.88 to 1.04), *P* = 0.22, *I* ^2^ = 31%. In the single study of Kleine-Brueggeney et al. \[[@B10]\], the total success rate was 15% (6/40) with the air-Q and 3% (1/40) with the Aura-I.

### 3.3.2. The Rate of Successful Intubation at First Attempt {#sec3.3.2}

The rate of successful intubation at first attempt in air-Q was compared to other airway devices in four studies \[[@B27], [@B13], [@B11], [@B9]\]. The combined results showed no evidence of difference in the rate of successful intubation at first attempt in air-Q compared to other airway devices. However, the result showed a tendency of the rate of successful intubation at first attempt in air-Q which was higher than other airway devices, RR 1.08 (95% CI 0.99 to 1.17), *P* = 0.29, *I* ^2^ = 20%.

### 3.3.3. Time to Intubate {#sec3.3.3}

The time to intubation was compared to other airway devices in five studies \[[@B27], [@B13], [@B11], [@B9], [@B10]\]. The combined results showed no evidence of a difference in the time to intubation, MD 1.341 (95% CI −4.44 to 7.13), *P* = 0.04, *I* ^2^ = 60%. Subgroup analyses were performed based on airway devices, SADs, fiberoptic guided. The combined results of four studies \[[@B13], [@B11], [@B9], [@B10]\] which compared air-Q and other SADs showed no evidence of difference, MD −0.18 (95% CI −6.20 to 5.84), *P* = 0.07, *I* ^2^ = 58%. Also, in a single study of Sohn et al. \[[@B27]\], there was no difference in time to intubation between free-handed and air-Q assisted tracheal intubation (*P* = 0.13).

3.4. Fiberoptic View Score {#sec3.4}
--------------------------

### 3.4.1. Best Scenario {#sec3.4.1}

The fiberoptic view of best scenario in air-Q was compared to other SADs in nine studies \[[@B12]--[@B10]\]. The best scenario of fiberoptic view was better through the air-Q than other SADs, RR 1.59 (95% CI 1.28 to 1.96), *P* = 0.05, *I* ^2^ = 49% ([Figure 3](#fig3){ref-type="fig"}). Performing subgroup analysis based on the generations of the airway devices, the best scenario of fiberoptic view in air-Q was better than first generations of SADs \[[@B12], [@B14], [@B9], [@B8]\], RR 2.03 (95% CI 1.42 to 2.92), *P* = 0.19, *I* ^2^ = 37%. Moreover, the best scenario of fiberoptic view in air-Q was better than second generations of SADs \[[@B13], [@B11], [@B15], [@B7], [@B10]\], RR 1.35 (95% CI 1.05 to 1.75), *P* = 0.15, *I* ^2^ = 40%.

### 3.4.2. Worst Scenario {#sec3.4.2}

The fiberoptic view of worst scenario in air-Q was compared to other SADs in nine studies \[[@B12]--[@B10]\]. The worst scenario of fiberoptic view showed no evidence of difference in the air-Q compared to other SADs, RR 1.10 (95% CI 0.59 to 2.07), *P* = 0.54, *I* ^2^ = 0%. Performing subgroup analysis based on the generations of airway devices, the worst scenario of fiberoptic view in air-Q showed no evidence of difference compared to first generation of SADs, RR 0.78 (95% CI 0.30 to 2.03), *P* = 0.57, *I* ^2^ = 0%. Also, there was no evidence of difference in the worst scenario of fiberoptic view in air-Q compared to second generation of SADs, RR 1.44 (95% CI 0.62 to 3.34), *P* = 0.25, *I* ^2^ = 27%.

3.5. Safety Analyses {#sec3.5}
--------------------

### 3.5.1. Blood Staining on Device {#sec3.5.1}

The incidence of blood staining on device was compared in six studies \[[@B12]--[@B14], [@B15]--[@B8]\]. There was no evidence of difference for the incidence of blood staining on device, RR 0.57 (95% CI 0.22 to 1.50), *P* = 0.53, *I* ^2^ = 0%. However, in the single study of Girgis et al. \[[@B9]\], the incidence of blood staining on device was significantly higher in patients with CobraPLA than Air-Q (30% versus 6.7%).

### 3.5.2. Sore Throat {#sec3.5.2}

The incidence of sore throat was compared in three studies \[[@B14], [@B9], [@B8]\]. The air-Q showed lower incidence of sore throat than other airway devices, RR 0.45 (95% CI 0.24 to 0.85), *P* = 0.41, *I* ^2^ = 0%.

### 3.5.3. Desaturation {#sec3.5.3}

The incidence of desaturation was compared in five studies \[[@B12], [@B13], [@B15]--[@B8]\]. There was no evidence of difference for the incidence of desaturation, RR 1.70 (95% CI 0.30 to 9.59), *P* = 0.79, *I* ^2^ = 0%.

### 3.5.4. Laryngospasm {#sec3.5.4}

The incidence of laryngospasm was compared in three studies \[[@B12], [@B9], [@B8]\]. There was no evidence of difference for the incidence of laryngospasm, RR 0.73 (95% CI 0.15 to 3.58), *P* = 0.78, *I* ^2^ = 0%.

### 3.5.5. Publication Bias {#sec3.5.5}

There was no evidence of publication bias detected by Egger\'s linear regression test and funnel plot. There was no *P* value of Egger\'s regression test that was showed to be \<0.1 which is indicative of publication bias.

4. Discussion {#sec4}
=============

The major finding of our meta-analysis was that air-Q is more difficult to insert than other airway devices. Also, the total success rate of intubation and the rate of successful intubation at first attempt showed a tendency lower than other airway devices. However, the fiberoptic view in best scenario was better in air-Q than other SADs. Also, in a safety analysis, the incidence of sore throat was lower in air-Q than other airway devices. The combined analysis of OLP, success rate of device insertion, insertion time, time to intubation, and the worst scenario of fiberoptic view could not reveal the difference between air-Q and other airway devices.

A tendency of higher success rate of intubation at first attempt in air-Q than other airway devices might be caused by better view of fiberoptic videoscope of air-Q. Using fiberoptic bronchoscope to guide tracheal intubation through a SAD is an established technique for securing the airway in children when conventional laryngoscopy is failed \[[@B11]\]. Also, SAD provides the ability to overcome upper airway obstruction and provision of a hands-free airway with a relatively straightforward path to the larynx \[[@B4], [@B27], [@B11]\]. The total success rate of blind intubation in Kleine-Brueggeney et al.\'s study was only 10% (6/60), while the total success rate of air-Q involving four studies which used air-Q as a fiberoptic guidance for intubation \[[@B27], [@B13], [@B11], [@B9]\] was 82.5% (147/178). Because of high incidence of worst scenario in pediatric patients and potential injury to the epiglottis or the glottis, blind intubations through SADs are not recommended in several studies \[[@B10], [@B28], [@B29]\]. The infants have large and floppy epiglottis preventing visualization of glottis \[[@B29]\]. In a pilot study of Sinha, the incidence of best scenario of fiberoptic bronchoscopy was higher in infants compared to other studies aimed at children \[[@B28]--[@B30]\]. In conclusion, it is recommended that SGA be used as a fiberoptic bronchoscope guidance of tracheal intubation not as a guide of blind intubation in children. Also, further studies should be needed to apply the result of this study according to patients\' age.

Performing the subgroup analysis, OLP was higher in air-Q than in Aura-I. The possible reasons for better OLP in air-Q are due to the unique features which include (i) curved and rigid airway tube which approximates the upper oropharyngeal airway with the glottis, (ii) mask ridges which improve the transverse stability of the bowl and support the lateral cuff seal, and (iii) raised mask heel \[[@B12], [@B14], [@B24]\]. Even though i-gel has shown higher airway leak pressure compared with other airway devices in children \[[@B31]\], the subgroup analysis showed no evidence of difference. These unique features of air-Q, especially raised mask heel, would have caused better OLP; otherwise they caused the following issues. The insertion of air-Q was more difficult and needed longer time compared to other SADs.

There are SADs which are simply "airway device" which may or may not protect against aspiration in the event of regurgitation. These SADs are called first generation including classic LMA, LMA-Flexible, laryngeal tube, and Cobra Perilaryngeal Airway. Second-generation SADs including LMA ProSeal, LMA Supreme, and i-gel provide a higher leak pressure and offer a drain tube to separate the respiratory and gastrointestinal tracts and minimize the risk of aspiration \[[@B32], [@B33]\]. Air-Q, classified in second-generation SAD \[[@B34]\], showed no evidence of difference in OLP compared to first-generation SADs in this meta-analysis. This result suggests that air-Q has little advantage in OLP compared to first-generation SADs and no further studies would be needed.

Through safety analysis, the incidence of sore throat was lower in patients in air-Q than other airway devices including CobraPLA and LMA. This result can be associated with the lower incidence of blood staining on device in air-Q than CobraPLA. Comparing CobraPLA and air-Q, "Cobra head" of the CobraPLA is more stiff in comparison with the cuff of other SADs including the air-Q which lead to more mucosal injury \[[@B9]\]. Therefore, we suggest that air-Q might be less traumatic SAD compared to other airway devices.

In two studies, self-pressurized air-Q was used rather than air-Q with balloon \[[@B14], [@B15]\]. Self-pressurized air-Q has an inner aperture at the junction of the airway tube and the mask cuff, creating an open airspace between the two and allowing the pressure to be self-regulated, which might provide easier device insertion and reduced risk for prolonged overinflation of the cuff and pressure-related injuries to the pharyngeal mucosa without the need for cuff pressure monitoring \[[@B14]\]. To rule out the effect of difference between air-Q which requires cuff inflation and self-pressurized air-Q, subgroup and sensitive analysis was performed. However, no result was changed through subgroup analysis and sensitive analysis.

There are some limitations in our study. First, because of air-Q being a newly developed SAD and a large variety of study designs, the number of studies involved in each subgroup was small. Second, large difference in the operator\'s experience (from trainee to senior anesthesiologists) could be a confounding factor.

In summary, we found that the air-Q could be a safe substitute for other intubating laryngeal mask airway devices and might provide better fiberoptic bronchoscopic view and shorter time to guide intubation.
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===========================
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![PRISMA flow diagram of the search, inclusion, and exclusion of randomized controlled trials.](BMRI2016-6406391.001){#fig1}

![Forest plot for ease of insertion. The figure depicted individual trials as filled squares with relative size of sample size and solid line as the 95% confidence interval of the difference. The diamond shape indicates the pooled estimate and uncertainty for the combined effect.](BMRI2016-6406391.002){#fig2}

![Forest plot for the fiberoptic view of best scenario. The figure depicted individual trials as filled squares with relative size of sample size and solid line as the 95% confidence interval of the difference. The diamond shape indicates the pooled estimate and uncertainty for the combined effect.](BMRI2016-6406391.003){#fig3}

###### 

Summary of studies included.

  Source                                     Number of patients   Sex (M/F)      Age              Weight         Height          ASA
  ------------------------------------------ -------------------- -------------- ---------------- -------------- --------------- ---------
  Sohn et al. 2014 \[[@B27]\]                80                   Not reported   8 (6)^*∗*^       8 (2)          71 (8)          1, 2, 3
  Jagannathan et al. 2012 \[[@B12]\]         100                  Not reported   19 (6)^*∗*^      11 (1)         Not reported    1, 2
  Jagannathan et al. 2012 \[[@B13]\]         120                  85/35          2 (1)^*∗*^       12 (4)         89 (23)         1, 2, 3
  Jagannathan et al. 2012 \[[@B14]\]         60                   38/22          7 (2)^*∗*^       25 (3)         Not reported    1, 2, 3
  Jagannathan et al. 2015 \[[@B11]\]         96                   Not reported   2.2              12.3           84.5            1, 2, 3
  Kim et al. 2015 \[[@B15]\]                 79                   76/3           2.8 (1.9)^*∗*^   14.6 \[4.9\]   88.6 \[16.8\]   1, 2
  Girgis et al. 2014 \[[@B9]\]               60                   30/20          3.9 (1.5)^*∗*^   16.5 \[3.1\]   91.8 \[11.2\]   1, 2
  Darlong et al. 2014 \[[@B8]\]              50                   39/11          8^*∗*^           6.5 (2.1)      7.2 (1.9)       1, 2
  Darlong et al. 2015 \[[@B7]\]              64                   45/19          8.7 (2.8)^*∗*^   6.6 (1.7)      Not reported    1, 2
  Kleine-Brueggeney et al. 2015 \[[@B10]\]   80                   43/37          4.3              16.3           116             1, 2, 3

ASA: American Society of Anesthesiology Classification; age: years or months^*∗*^; FOB: fiberoptic bronchoscopy.

###### 

Summary of studies included.

  Source                                     Amount and experience of device user                                                                                                                                                                                                                                                                   Type of surgery                                                                        Allowance of insertion trials   Intervention/control
  ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------- ------------------------------- --------------------------------------
  Sohn et al. 2014 \[[@B27]\]                Attending or trainee, trainee having minimal prior experience with pediatric fiberoptic bronchoscopes and watched a video outlining the steps for fiberoptic guided tracheal intubation through an air-Q before participating                                                                          Elective surgical procedures requiring tracheal intubation under general anaesthesia   3                               Air-Q/fiberoptic tracheal intubation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Jagannathan et al. 2012 \[[@B12]\]         Two anesthesiologists experienced in using both devices                                                                                                                                                                                                                                                Elective outpatient surgery in the supine position                                     2                               Air-Q/LMA-Unique
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Jagannathan et al. 2012 \[[@B13]\]         Five study investigators who used the air-Q for tracheal intubation in at least 50 patients and who have minimal experience with the Aura-I prior to this study                                                                                                                                        Elective surgery under general endotracheal anaesthesia                                3                               Air-Q/Aura-I
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Jagannathan et al. 2012 \[[@B14]\]         Three study investigators experienced in the use of both devices                                                                                                                                                                                                                                       Elective outpatient surgery with planned airway management with a LMA device           2                               Air-Q/LMA-Unique
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Jagannathan et al. 2015 \[[@B11]\]         Anaesthesiology trainees, resident or fellow from clinical anaesthesia 2, 3, or 4 who had not previously performed FOB-guided tracheal intubation through an SGA in children → and received a brief lecture and viewed a video outlining the steps for FOB-guided tracheal intubation through an SGA   Elective surgery under general endotracheal anaesthesia                                3                               Air-Q/i-gel
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Kim et al. 2015 \[[@B15]\]                 Two anesthesiologists experienced in inserting supraglottic airway devices in at least 100 pediatric patients                                                                                                                                                                                          Elective surgery under general endotracheal anaesthesia                                2                               Air-Q/i-gel
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Girgis et al. 2014 \[[@B9]\]               Not reported                                                                                                                                                                                                                                                                                           Elective surgery under general endotracheal anaesthesia                                2                               Air-Q/CobraPLA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Darlong et al. 2014 \[[@B8]\]              Not reported                                                                                                                                                                                                                                                                                           Cataract or glaucoma surgery                                                           3                               Air-Q/Flexible laryngeal mask
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Darlong et al. 2015 \[[@B7]\]              Not reported                                                                                                                                                                                                                                                                                           Elective surgery with tracheal intubation                                              3                               Air-Q/Aura-I
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Kleine-Brueggeney et al. 2015 \[[@B10]\]   Senior anesthesiologists from the pediatric anaesthesia division                                                                                                                                                                                                                                       Elective ophthalmic surgery                                                            3                               Air-Q/Aura-I

###### 

Summary of studies included.

  Source                                     Device size                                                           Use of muscle relaxant   Induction method                                                                                                                                Maintenance agent
  ------------------------------------------ --------------------------------------------------------------------- ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------
  Sohn et al. 2014 \[[@B27]\]                According to manufacturer guidelines based on the patient\'s weight   Rocuronium               8% sevoflurane, 70% nitrous oxide, rocuronium 0.6 mg/kg                                                                                         Sevoflurane
                                                                                                                                                                                                                                                                                            
  Jagannathan et al. 2012 \[[@B12]\]         Size 2 and size 1.5                                                   No                       Sevoflurane with 70% nitrous oxide and fentanyl 1 *μ*g/kg                                                                                       Sevoflurane
                                                                                                                                                                                                                                                                                            
  Jagannathan et al. 2012 \[[@B13]\]         Based on the manufacturer guidelines                                  Rocuronium               Sevoflurane with 70% nitrous oxide and fentanyl 1 *μ*g/kg                                                                                       Sevoflurane
                                                                                                                                                                                                                                                                                            
  Jagannathan et al. 2012 \[[@B14]\]         Air-Q: size 2 and LMA: 2.5                                            No                       Sevoflurane with 70% nitrous oxide and fentanyl 1 *μ*g/kg                                                                                       Sevoflurane with 60% nitrous oxide
                                                                                                                                                                                                                                                                                            
  Jagannathan et al. 2015 \[[@B11]\]         Based on manufacturer guidelines                                      Rocuronium               70% nitrous oxide and sevoflurane 8%                                                                                                            Sevoflurane 3%
                                                                                                                                                                                                                                                                                            
  Kim et al. 2015 \[[@B15]\]                 Based on manufacturer guidelines                                      No                       Propofol 2 mg/kg or 6% sevoflurane                                                                                                              3-4% sevoflurane
                                                                                                                                                                                                                                                                                            
  Girgis et al. 2014 \[[@B9]\]               Based on manufacturer guidelines                                      Atracurium               Premedication with midazolam 0.5 mg·kg, 8% sevoflurane, 100% oxygen, fentanyl 1 *μ*g/kg, atracurium 0.5 mg/kg                                   Not reported
                                                                                                                                                                                                                                                                                            
  Darlong et al. 2014 \[[@B8]\]              Depending upon body weight                                            Atracurium               Sevoflurane 2--8%, fentanyl 1 *μ*g·kg, atracurium 0.25 mg/kg                                                                                    Isoflurane 1-2%
                                                                                                                                                                                                                                                                                            
  Darlong et al. 2015 \[[@B7]\]              Depending upon body weight                                            Atracurium               Sevoflurane 2--8%, fentanyl 1 *μ*g·kg, atracurium 0.25 mg/kg                                                                                    Isoflurane 1-2%
                                                                                                                                                                                                                                                                                            
  Kleine-Brueggeney et al. 2015 \[[@B10]\]   Based on manufacturer guidelines                                      Atracurium               Sevoflurane 6% for inhalation induction, propofol 4 mg/kg or thiopental 6 mg/kg for intravenous induction, fentanyl or alfentanil, atracurium   Not commented

LMA: laryngeal mask airway; ETT: endotracheal tube.

###### 

Risk of bias in included randomized controlled trials.

  Biases/references                          Random sequence generation   Allocation concealment   Incomplete outcome data   Blinding of participants   Blinding of outcome assessment   Selective reporting   Other bias
  ------------------------------------------ ---------------------------- ------------------------ ------------------------- -------------------------- -------------------------------- --------------------- ------------
  Sohn et al. 2014 \[[@B27]\]                Low risk                     Unclear                  Low risk                  Unclear                    Unclear                          Low risk              Low risk
  Jagannathan et al. 2012 \[[@B12]\]         Low risk                     Low risk                 Low risk                  Unclear                    Unclear                          Low risk              Low risk
  Jagannathan et al. 2012 \[[@B13]\]         Low risk                     Unclear                  Low risk                  Unclear                    Unclear                          Low risk              Low risk
  Jagannathan et al. 2012 \[[@B14]\]         Low risk                     Low risk                 Low risk                  Unclear                    Unclear                          Low risk              Low risk
  Jagannathan et al. 2015 \[[@B11]\]         Low risk                     Unclear                  Low risk                  Unclear                    Unclear                          Low risk              Low risk
  Kim et al. 2015 \[[@B15]\]                 Low risk                     Low risk                 Low risk                  Unclear                    Unclear                          Low risk              Low risk
  Girgis et al. 2014 \[[@B9]\]               Low risk                     Low risk                 Low risk                  Unclear                    Unclear                          Low risk              Low risk
  Darlong et al. 2014 \[[@B8]\]              Low risk                     Low risk                 Low risk                  Unclear                    Unclear                          Low risk              Low risk
  Darlong et al. 2015 \[[@B7]\]              Low risk                     Low risk                 Low risk                  Unclear                    Unclear                          Low risk              Low risk
  Kleine-Brueggeney et al. 2015 \[[@B10]\]   Low risk                     Low risk                 Low risk                  Unclear                    Unclear                          Low risk              Low risk
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